These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24915752)

  • 1. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.
    van Pesch V; Bartholomé E; Bissay V; Bouquiaux O; Bureau M; Caekebeke J; Debruyne J; Declercq I; Decoo D; Denayer P; De Smet E; D'hooghe M; Dubois B; Dupuis M; Sankari SE; Geens K; Guillaume D; van Landegem W; Lysandropoulos A; de Noordhout AM; Medaer R; Melin A; Peeters K; Ba RP; Retif C; Seeldrayers P; Symons A; Urbain E; Vanderdonckt P; Van Ingelghem E; Vanopdenbosch L; Vanroose E; Van Wijmeersch B; Willekens B; Willems C; Sindic C
    Acta Neurol Belg; 2014 Sep; 114(3):167-78. PubMed ID: 24915752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
    Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study.
    Borriello G; Prosperini L; Mancinelli C; Giannì C; Fubelli F; Pozzilli C
    Eur J Neurol; 2012 May; 19(5):783-7. PubMed ID: 22054236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.
    O'Connor P; Goodman A; Kappos L; Lublin F; Polman C; Rudick RA; Hauswirth K; Cristiano LM; Forrestal F; Duda P
    Neurology; 2014 Jul; 83(1):78-86. PubMed ID: 24898925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.
    Kappos L; O'Connor PW; Polman CH; Vermersch P; Wiendl H; Pace A; Zhang A; Hotermans C
    J Neurol; 2013 May; 260(5):1388-95. PubMed ID: 23292204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
    Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V
    Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
    Butzkueven H; Kappos L; Wiendl H; Trojano M; Spelman T; Chang I; Kasliwal R; Jaitly S; Campbell N; Ho PR; Licata S;
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):660-668. PubMed ID: 32234967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study.
    Sousa L; de Sa J; Sa MJ; Cerqueira JJ; Martins-Silva A;
    Rev Neurol; 2014 Nov; 59(9):399-406. PubMed ID: 25342053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.
    Lublin FD; Cutter G; Giovannoni G; Pace A; Campbell NR; Belachew S
    Mult Scler Relat Disord; 2014 Nov; 3(6):705-11. PubMed ID: 25891549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M; Schiavetti I; De Mercanti SF; Piazza F; Gned D; Brescia Morra V; Lanzillo R; Ghezzi A; Bianchi A; Salemi G; Realmuto S; Sola P; Vitetta F; Cavalla P; Paolicelli D; Trojano M; Sormani MP; Durelli L
    JAMA Neurol; 2014 Aug; 71(8):954-60. PubMed ID: 24977406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H;
    Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
    Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.
    Butzkueven H; Kappos L; Pellegrini F; Trojano M; Wiendl H; Patel RN; Zhang A; Hotermans C; Belachew S;
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1190-7. PubMed ID: 24532785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers.
    Oliveira EM; Simm RF; Dasic G; Morais MM; Perreira SL; Callegaro D
    Arq Neuropsiquiatr; 2015 Sep; 73(9):736-40. PubMed ID: 26352489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
    Rossi S; Motta C; Studer V; De Chiara V; Barbieri F; Monteleone F; Fornasiero A; Coarelli G; Bernardi G; Cutter G; Stüve O; Salvetti M; Centonze D
    Eur J Neurol; 2013 Jan; 20(1):87-94. PubMed ID: 22741530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
    J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
    Kallweit U; Jelcic I; Braun N; Fischer H; Zörner B; Schreiner B; Sokolov AA; Martin R; Weller M; Linnebank M
    Clin Neuropharmacol; 2012; 35(2):77-80. PubMed ID: 22318192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.